Novartis delivers strong sales, double digit core operating income growth and launches Zolgensma and Piqray in second quarter; sales and profit guidance increased

  • Continuing operations[1] net sales up 8% (cc[2], +4% USD) driven by:
    • Cosentyx at USD 858 million, +25% (cc) mainly driven by continued strong US growth (+31%)
    • Entresto grew to USD 421 million, +81% (cc) with increased initiation in hospital and ambulatory settings
    • Oncology sales grew 9% (cc) driven by growth from Lutathera (USD 109 million), Kisqali (USD 111 million) and Kymriah (USD 58 million) in the second quarter
    • Sandoz sales grew 3% (cc, -1% USD) as ex-US growth more than …
/by